Vaccinology of poliomyelitis (Q39425504)

11 September 2017

1 reference

title

Vaccinology of poliomyelitis (English)

1 reference

11 September 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099644

5 August 2023

physiology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099644

5 August 2023

medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099644

5 August 2023

infection

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099644

5 August 2023

public health

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6099644

5 August 2023

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

5 August 2023

2

J Salk

1 reference

11 September 2017

1

D Salk

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 March 1984

1 reference

full work available at URL

11 September 2017

https://api.elsevier.com/content/article/PII:S0264410X98900354?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

https://api.elsevier.com/content/article/PII:S0264410X98900354?httpAccept=text/plain

5 August 2023

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

5 August 2023

1 reference

11 September 2017

2

1 reference

11 September 2017

1

1 reference

11 September 2017

59-74

1 reference

Tapping the immunological repertoire to produce antibodies of predetermined specificity

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

1 reference

7 January 2021

Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Antibody response of infants in tropics to five doses of oral polio vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Immunization against poliomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

The immunological response of Nigerian infants to attenuated and inactivated poliovaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

A review of theoretical, experimental, and practical considerations in the use of formaldehyde for the inactivation of poliovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Inactivation of concentrated purified poliovirus suspensions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Poliomyelitis vaccine in the fall of 1955

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Control of Influenza and Poliomyelitis with Killed Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Considerations in the preparation and use of poliomyelitis virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Antigenic potency of poliomyelitis vaccine; influence on degree and duration of vaccine effect

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

How many injections of poliomyelitis vaccine for effective and durable immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Persistence of immunity after administration of formalin-treated poliovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Poliomyelitis in the Netherlands before and after vaccination with inactivated poliovaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Preconceptions about vaccination against paralytic poliomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating poliovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Vaccination Against Paralytic Poliomyelitis Performance and Prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

A concept of the mechanism of immunity for preventing paralysis in poliomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Poliomyelitis Immunization: Mass use of oral vaccine in the United States might prevent definitive evaluation of either vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

OBSERVED AND EXPECTED POLIOMYELITIS IN THE UNITED STATES, 1958-1961

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

National participation trends, 1955-61, in the poliomyelitis vaccination program

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Present position of immunization against poliomyelitis with live virus vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Intratypic Serodifferentiation of Poliomyelitis Virus Strains by Strain-Specific Antisera

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Multiple Genetic Changes Can Occur in the Oral Poliovaccines upon Replication in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Evolution of poliovirus since introduction of attenuated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Vaccination Against Poliomyelitis: an Ounce of Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Poliomyelitis in an immunized community

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2990035-4

7 January 2021

Present state and developments in the production of inactivated poliomyelitis vaccine

2

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Antibody response to oral polio vaccine in infancy

5 August 2023

12

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

An appraisal of polio immunization in Nigeria and other tropical African Countries

5 August 2023

16

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Antibody to poliovirus in older children and young adults in Israel and the use of poliovaccines for the immunization of the seronegatives

5 August 2023

17

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

A controlled trial with inactivated poliovaccine

5 August 2023

18

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Quadruple vaccines containing pertussis and poliomyelitis vaccines

5 August 2023

22

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Antibody stimulation in individuals without demonstrable poliovirus antibodies following a fifth injection of inactivated poliovirus vaccine

5 August 2023

40

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Requirements for persistent immunity to poliomyelitis

5 August 2023

44

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden

5 August 2023

50

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

POLIO IMMUNIZATION AND THE HERD EFFECT

5 August 2023

54

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Experiences of vaccination with inactivated poliovirus vaccine in Sweden

5 August 2023

62

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Eradication of poliomyelitis in the United States

5 August 2023

64

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Widespread distribution of poliomyelitis in households attacked by the disease

5 August 2023

70

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Eradication of poliomyelitis in the United States

5 August 2023

72

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

5 August 2023

79

1

1617

1977

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

Poliomyelitis in the Netherlands

5 August 2023

87

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(98)90035-4

5 August 2023

Identifiers

1 reference

11 September 2017

1 reference